• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Exosome therapeutics dev Evox raises $45m in Series B

September 4, 2018 By Fink Densford

Evox Therapeutics

Exosome therapeutics company Evox Therapeutics said today that it raised $45.4 million (GBP £35.5 million) in a Series B round of financing.

The funding round was led by Redmile Group, new investments from GV, formerly known as Google Ventures, and Cowen Healthcare Investments, the Oxford, U.K.-based company said. The round was joined by Panacea Healthcare Venture, Borealis Ventures and existing investors Oxford Sciences Innovation and Oxford University.

Evox said it is using exosomes to allow certain drugs to reach “previously inaccessible tissues and compartments,” including crossing the blood brain barrier, intracellular delivery of biologics and extra-hepatic delivery of RNA therapeutics.

“We believe exosomes represent an important emerging therapeutic approach with potentially broad applicability, and we are enthusiastic to partner with the Evox team,” Redmile Group founder & portfolio manager Jeremy Green said in a prepared statement.

Proceeds from the round will go towards supporting the company’s exosome-based therapeutics pipeline, including several rare disease assets moving towards the clinic and the continued development of its exosome drug platform.

“We are very pleased for the support of both our existing and new investors who participated in this Series B financing. Over the past several years we have continued to expand the reach of our exosome platform, translating that knowledge into impactful therapeutics for our internal pipeline and for partners. We have also vigorously expanded our robust intellectual property portfolio, built our internal R&D teams, and put in place advisory boards who are offering deep insights as we advance key programmes towards clinical development. We are excited by the inherent transformational potential of our exosome technology, which significantly improves and enables the delivery of a wide range of therapeutic molecules, including antibodies, proteins, nucleic acids, and small molecules. This additional funding will enable us to advance our pipeline of novel exosome-based therapeutics towards the clinic and allow continued expansion of our world-leading exosome platform,” CEO Dr. Antonin de Fougerolles said in a press release.

Filed Under: Business/Financial News, Featured, Funding Roundup Tagged With: evoxtherapeutics

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS